Ved 36. måned havde 80, 4% af disse patienter stadig et beskyttende antistofniveau (anti- HBs- titer ≥ 10 mIU/ ml), sammenlignet med 51, 3% i gruppen af patienter, som modtog en kommercielt tilgængelig hepatitis B- vaccine.
At month 36, 80.4% of these patients retained protective antibody levels (anti-HBs titres ≥ 10mIU/ ml), as compared to 51.3% of patients who received a commercially available hepatitis B vaccine.